It is strange that when talking about efficacy, they try to talk...

It is strange that when talking about efficacy, they try to talk about the flu antivirals as a group, and when talking about some advantages of usage and recommending Tamiflu, they try to mention Tamiflu only and talkpositively as much as possible.

Is my understand and view biased?

Furthermore, it is not surprising that those who make the decision have direct or indirect holdings in Gealid or Roche give the market caps of those companies.


I strongly believe that our biota shareholdings will be heavily diluted before we can get any decent return from the company. Those big "sharks" are all looking at biota and try to take a big bit at it when there is any profit. Our holdings have been diluted by the Free Share options for PC and others, the last two useless and costly acquisitions and more recently free shares and share options to the newly appointed executives.



Just my opinions.